Non-Hodgkin Lymphoma Linked to Q Fever Bacterium
By LabMedica International staff writers Posted on 25 Oct 2015 |

Image: A dry fracture of a Vero cell exposing the contents of a vacuole where Coxiella burnetii, the causative agent of Q fever, are rapidly growing (Photo courtesy of National Institutes of Health).
The incidence of non-Hodgkin lymphoma (NHL), associated with significant mortality, is increasing in many regions, making it a global health challenge for the coming years.
The bacterium Coxiella burnetii causes Q fever, which is an infectious disease that is primarily transmitted through the excrement of cattle, sheep, and goats and humans contract it from these animals is associated with an increased risk of lymphoma.
A large team of French scientists led by those at the Aix-Marseille University (Marseille, France) screened 1,468 patients treated at the French National Referral Center for Q fever from 2004 to 2014. Acute Q fever was defined by the association of clinical symptoms (fever, hepatitis and/or pneumonia) with the serological criteria of a phase II immunoglobulin G (IgG) titer equal to or greater than 200 and a phase II IgM titer equal to or greater than 50, seroconversion or a positive polymerase chain reaction (PCR) and no endocarditis.
Formalin-fixed and paraffin-embedded biopsy samples were analyzed by an expert hematopathologist in all cases to confirm the diagnosis of lymphoma. Immunofluorescence (IF), 16S ribosomal ribonucleic acid (rRNA) fluorescence in situ hybridization (FISH) and genomic DNA FISH were performed as well as other diagnostic techniques. The amount of interleukin-10 (IL-10) in sera was determined using specific immunoassays (R&D Systems; Minneapolis, MN, USA). IL10 and Tumor necrosis factors (TNF) were measured in supernatants from non-stimulated and C. burnetii stimulated peripheral blood mononuclear cells (PBMC).
The team found, based on their analysis, that patients with Q fever were 25 times more likely to develop diffuse large B-cell lymphoma than those without the infection. In addition, the odds of lymphoma in patients with persistent concentrated infections are higher than those with other forms of Q fever. The investigators observed that Q fever patients with lymphoma demonstrated overproduction of the critical anti-inflammatory pathway IL-10, suggesting that suppression of the immune system may have allowed the lymphoma cells to evade immune detection and multiply.
Didier Raoult, MD, PhD, the senior author of the study, said, “As we continue to learn more about the association between C. burnetii and lymphoma, these results should encourage clinicians to survey high-risk patients as early as possible for potential cancer. Ultimately, this early diagnosis and treatment would improve outcomes for Q fever patients who subsequently develop lymphoma, particularly those with B-cell non-Hodgkin lymphoma.” The study was published on October 13, 2015, in the journal Blood .
Related Links:
Aix-Marseille University
R&D Systems
The bacterium Coxiella burnetii causes Q fever, which is an infectious disease that is primarily transmitted through the excrement of cattle, sheep, and goats and humans contract it from these animals is associated with an increased risk of lymphoma.
A large team of French scientists led by those at the Aix-Marseille University (Marseille, France) screened 1,468 patients treated at the French National Referral Center for Q fever from 2004 to 2014. Acute Q fever was defined by the association of clinical symptoms (fever, hepatitis and/or pneumonia) with the serological criteria of a phase II immunoglobulin G (IgG) titer equal to or greater than 200 and a phase II IgM titer equal to or greater than 50, seroconversion or a positive polymerase chain reaction (PCR) and no endocarditis.
Formalin-fixed and paraffin-embedded biopsy samples were analyzed by an expert hematopathologist in all cases to confirm the diagnosis of lymphoma. Immunofluorescence (IF), 16S ribosomal ribonucleic acid (rRNA) fluorescence in situ hybridization (FISH) and genomic DNA FISH were performed as well as other diagnostic techniques. The amount of interleukin-10 (IL-10) in sera was determined using specific immunoassays (R&D Systems; Minneapolis, MN, USA). IL10 and Tumor necrosis factors (TNF) were measured in supernatants from non-stimulated and C. burnetii stimulated peripheral blood mononuclear cells (PBMC).
The team found, based on their analysis, that patients with Q fever were 25 times more likely to develop diffuse large B-cell lymphoma than those without the infection. In addition, the odds of lymphoma in patients with persistent concentrated infections are higher than those with other forms of Q fever. The investigators observed that Q fever patients with lymphoma demonstrated overproduction of the critical anti-inflammatory pathway IL-10, suggesting that suppression of the immune system may have allowed the lymphoma cells to evade immune detection and multiply.
Didier Raoult, MD, PhD, the senior author of the study, said, “As we continue to learn more about the association between C. burnetii and lymphoma, these results should encourage clinicians to survey high-risk patients as early as possible for potential cancer. Ultimately, this early diagnosis and treatment would improve outcomes for Q fever patients who subsequently develop lymphoma, particularly those with B-cell non-Hodgkin lymphoma.” The study was published on October 13, 2015, in the journal Blood .
Related Links:
Aix-Marseille University
R&D Systems
Latest Immunology News
- Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
- Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
- Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
- Cerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
- New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
- Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
- Novel Analytical Method Tracks Progression of Autoimmune Diseases
- 3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response
- Blood Test for Fungal Infections Could End Invasive Tissue Biopsies
- Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies
- New Discovery in Blood Immune Cells Paves Way for Parkinson's Disease Diagnostic Test
- AI Tool Uses Routine Blood Tests to Predict Immunotherapy Response for Various Cancers
- Blood Test Can Predict How Long Vaccine Immunity Will Last
- Microfluidic Chip-Based Device to Measure Viral Immunity
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Simple Blood Test Improves Heart Attack and Stroke Risk Prediction
Troponin is a protein found in heart muscle cells that is released into the bloodstream when the heart is damaged. High-sensitivity troponin blood tests are commonly used in hospitals to diagnose heart... Read more
Blood Biomarker Test Could Detect Genetic Predisposition to Alzheimer’s
New medications for Alzheimer’s disease, the most common form of dementia, are now becoming available. These treatments, known as “amyloid antibodies,” work by promoting the removal of small deposits from... Read more
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Spit Test More Accurate at Identifying Future Prostate Cancer Risk
Currently, blood tests that measure the level of a protein called prostate-specific antigen (PSA) are commonly used to identify men at higher risk for prostate cancer. This test is typically used based... Read more
DNA Nanotechnology Boosts Sensitivity of Test Strips
Since the Covid-19 pandemic, most people have become familiar with paper-based rapid test strips, also known as lateral flow immunoassays (LFIAs). These tests are used to quickly detect biomarkers that... Read more
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more